Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
385,20 €
1,11 %
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Cantor Fitzgerald from $535.00 to $485.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at HC Wainwright from $550.00 to $478.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at BMO Capital Markets from $557.00 to $530.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at UBS Group AG from $582.00 to $553.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Corporation from $520.00 to $490.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $460.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Guggenheim from $558.00 to $546.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lowered by analysts at Evercore ISI from $510.00 to $475.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $456.00 price target on the stock, down previously from $458.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Citigroup Inc. from $550.00 to $575.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $517.00 to $530.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lowered by analysts at UBS Group AG from $553.00 to $546.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Amazon.com Inc. diskutieren